{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:25:40Z","timestamp":1794360340579,"version":"4.9.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019125","name":"Sorbonne Universit\u00e9","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100019125","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Association Fran\u00e7aise contre les Myopathies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"DOI":"10.1186\/s13395-025-00394-2","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:20:17Z","timestamp":1757377217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fighting for every beat: cardiac therapies in Duchenne muscular dystrophy"],"prefix":"10.1186","volume":"15","author":[{"given":"Antoine","family":"Muchir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"394_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","volume":"359","author":"AEH Emery","year":"2002","unstructured":"Emery AEH. The muscular dystrophies. Lancet. 2002;359:687\u201395.","journal-title":"Lancet"},{"key":"394_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1542\/peds.2014-2044","volume":"135","author":"PA Romitti","year":"2015","unstructured":"Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GKD, et al. Prevalence of Duchenne and Becker muscular dystrophies in the united States. Pediatrics. 2015;135:513\u201321.","journal-title":"Pediatrics"},{"key":"394_CR3","doi-asserted-by":"crossref","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers 2021;13.","DOI":"10.1038\/s41572-021-00248-3"},{"key":"394_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1083\/jcb.150.5.1209","volume":"150","author":"IN Rybakova","year":"2000","unstructured":"Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and Costameric actin. J Cell Biol. 2000;150:1209\u201314.","journal-title":"J Cell Biol"},{"key":"394_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbadis.2006.05.010","volume":"1772","author":"JM Ervasti","year":"2007","unstructured":"Ervasti JM. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta Mol Basis Dis. 2007;1772:108\u201317.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"394_CR6","doi-asserted-by":"crossref","unstructured":"Gumerson JD, Michele DE. The dystrophin-glycoprotein complex in the prevention of muscle damage. J Biomed Biotechnol. 2011; 2011:210797.","DOI":"10.1155\/2011\/210797"},{"key":"394_CR7","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA. 1993;90:3710\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"394_CR8","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.jacc.2016.02.081","volume":"67","author":"F Kamdar","year":"2016","unstructured":"Kamdar F, Garry DJ. Dystrophin-Deficient cardiomyopathy. J Am Coll Cardiol. 2016;67:2533\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"394_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yjmcc.2012.12.009","volume":"58","author":"N Shirokova","year":"2013","unstructured":"Shirokova N, Niggli E. Cardiac phenotype of Duchenne muscular dystrophy: insights from cellular studies. J Mol Cell Cardiol. 2013;58:217\u201324.","journal-title":"J Mol Cell Cardiol"},{"key":"394_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-G","volume":"26","author":"G Nigro","year":"1990","unstructured":"Nigro G, Comi LI, Politano L, Bain RJI. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990;26:271\u20137.","journal-title":"Int J Cardiol"},{"key":"394_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacbts.2021.11.004","volume":"7","author":"TI Schultz","year":"2022","unstructured":"Schultz TI, Raucci FJ Jr, Salloum FN. Cardiovascular disease in Duchenne muscular dystrophy. JACC Basic Transl Sci. 2022;7:608\u201325.","journal-title":"JACC Basic Transl Sci"},{"key":"394_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCIMAGING.110.960740","volume":"4","author":"D Verhaert","year":"2011","unstructured":"Verhaert D, Richards K, Rafael-Fortney JA, Raman SV. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotype considerations. Circ Cardiovasc Imaging. 2011;4:67\u201376.","journal-title":"Circ Cardiovasc Imaging"},{"key":"394_CR13","first-page":"947","volume":"11","author":"F Pennati","year":"2021","unstructured":"Pennati F, LoMauro A, D\u2019Angelo MG, Aliverti A. Non-invasive respiratory assessment in Duchenne muscular dystrophy: from clinical research to outcome measures. Life (Basel). 2021;11:947.","journal-title":"Life (Basel)"},{"key":"394_CR14","first-page":"CD003725","volume":"5","author":"E Matthews","year":"2016","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;5:CD003725.","journal-title":"Cochrane Database Syst Rev"},{"key":"394_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/genes11080837","volume":"11","author":"C Sun","year":"2020","unstructured":"Sun C, Shen L, Zhang Z, Xie X. Therapeutic strategies for Duchenne muscular dystrophy: an update. Genes (Basel). 2020;11:837.","journal-title":"Genes (Basel)"},{"key":"394_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.nmd.2023.09.004","volume":"33","author":"P Karachunski","year":"2023","unstructured":"Karachunski P, Townsend D. Systemic under treatment of heart disease in patients with Duchenne muscular dystrophy. Neuromusc Dis. 2023;33:776\u201381.","journal-title":"Neuromusc Dis"},{"key":"394_CR17","doi-asserted-by":"crossref","unstructured":"Novelli V, Canonico F, Laborante R, Manzoni M, Arcudi A, Pompilio G et al. Unraveling the genetic heartbeat: decoding cardiac involvement in Duchenne muscular dystrophy. Biomedicines 2025:13102.","DOI":"10.3390\/biomedicines13010102"},{"key":"394_CR18","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","volume":"131","author":"EM McNally","year":"2015","unstructured":"McNally EM, Kaltman JR, Benson W, Canter CE, Cripe LH, Duan D, et al. Contemporary cardiac issues in Duchenne muscular dystrophy. Circulation. 2015;131:1590\u20138.","journal-title":"Circulation"},{"key":"394_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5535\/arm.2017.41.2.306","volume":"41","author":"EY Kim","year":"2017","unstructured":"Kim EY, Lee JW, Suh MR, Choi WA, Kang SW, Oh HJ. Correlation of serum Creatin kinase level with pulmonary function in Duchenne muscular dystrophy. Ann Rehabil Med. 2017;41:306\u201312.","journal-title":"Ann Rehabil Med"},{"key":"394_CR20","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/cells11091417","volume":"11","author":"BJ Paleo","year":"2022","unstructured":"Paleo BJ, McElhanon KE, Bulgart HR, Banford KK, Beck EX, Sattler KM, et al. Reduced sarcolemmal membrane repair exacerbates striated muscle pathology in a mouse model of Duchenne muscular dystrophy. Cells. 2022;11:1417.","journal-title":"Cells"},{"key":"394_CR21","doi-asserted-by":"publisher","first-page":"647010","DOI":"10.3389\/fphys.2021.647010","volume":"12","author":"S Mareedu","year":"2021","unstructured":"Mareedu S, Million ED, Duan D, Babu GJ. Abnormal calcium handling in Duchenne muscular dystrophy: mechanisms and potential therapies. Front Physiol. 2021;12:647010.","journal-title":"Front Physiol"},{"key":"394_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/ijms24010362","volume":"24","author":"M Bencze","year":"2023","unstructured":"Bencze M. Mechanisms of myofiber death in muscular dystrophies: the emergence of the regulated forms of necrosis in myology. Int J Mol Sci. 2023;24:362.","journal-title":"Int J Mol Sci"},{"key":"394_CR23","doi-asserted-by":"publisher","first-page":"H846","DOI":"10.1152\/ajpheart.00688.2006","volume":"292","author":"IA Williams","year":"2007","unstructured":"Williams IA, Allen DG. Intracellular calcium handling in ventricular myocytes from Mdx mice. Am J Physiol Heart Circ Physiol. 2007;292:H846\u201355.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"394_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ceca.2009.06.002","volume":"46","author":"M Fanchaouy","year":"2009","unstructured":"Fanchaouy M, Polakova E, Jung C, Ogrodnik J, Shirokova N, Niggli E. Pathways of abnormal stress-induced Ca2+influx into dystrophic Mdx cardiomyocytes. Cell Calcium. 2009;46:114\u201321.","journal-title":"Cell Calcium"},{"key":"394_CR25","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1111\/j.1582-4934.2012.01630.x","volume":"16","author":"S Wagner","year":"2012","unstructured":"Wagner S, Knipp S, Weber C, Hein S, Schinkel S, Walther A, et al. The heart in Duchenne muscular dystrophy: early detection of contractile performance alteration. J Cell Mol Med. 2012;16:3028\u201336.","journal-title":"J Cell Mol Med"},{"key":"394_CR26","doi-asserted-by":"publisher","first-page":"27089","DOI":"10.31083\/RCM27089","volume":"26","author":"D D\u2019Amario","year":"2025","unstructured":"D\u2019Amario D, Arcudi A, Narducci ML, Novelli V, Canonico F, Parodi A, et al. Arrhythmic risk stratification and sudden cardiac death prevention in Duchenne muscular dystrophy: a critical appraisal. Rev Cardiovasc Med. 2025;26:27089.","journal-title":"Rev Cardiovasc Med"},{"key":"394_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrcardio.2013.213","volume":"11","author":"J Finsterer","year":"2014","unstructured":"Finsterer J, Cripe L. Treatment of dystrophin cardiomyopathies. Nat Rev Cardiol. 2014;11:168\u201379.","journal-title":"Nat Rev Cardiol"},{"key":"394_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562864231182934","volume":"16","author":"MNA Shah","year":"2023","unstructured":"Shah MNA, Yokota T. Cardiac therapies for Duchenne muscular dystrophy. Ther Adv Neurol Disord. 2023;16:1\u201317.","journal-title":"Ther Adv Neurol Disord"},{"key":"394_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","volume":"447","author":"EM Welch","year":"2007","unstructured":"Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87\u201391.","journal-title":"Nature"},{"key":"394_CR30","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.1023","volume":"49","author":"KR Wagner","year":"2001","unstructured":"Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, et al. Gentamycin treatment of Duchenne and Becker muscular dystrophy, due to nonsense mutations. Ann Neurol. 2001;49:706\u201311.","journal-title":"Ann Neurol"},{"key":"394_CR31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3390\/genes15111489","volume":"15","author":"J Leckie","year":"2024","unstructured":"Leckie J, Zia A, Yokota T. An updated analysis of exon-skipping applicability for Duchenne muscular dystrophy using the UMD-DMD database. Genes (Basel). 2024;15:1489.","journal-title":"Genes (Basel)"},{"key":"394_CR32","doi-asserted-by":"crossref","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"KRQ Lim","year":"2012","unstructured":"Lim KRQ, Woo S, Melo D, Huang Y, Dzierlega K, Shah MSA, et al. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2012;109:13763\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"394_CR33","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1489\u201398.","journal-title":"Lancet"},{"key":"394_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii L, Hildyard JCW, Li H, Sanchez-Ortiz E, Mireault A, Caballero D, et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science. 2018;362:86\u201391.","journal-title":"Science"},{"key":"394_CR35","doi-asserted-by":"publisher","first-page":"14454","DOI":"10.1038\/ncomms14454","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins D, et al. Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun. 2017;8:14454.","journal-title":"Nat Commun"},{"key":"394_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Catsellanos Rivera RM, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351:403\u20137.","journal-title":"Science"},{"key":"394_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","volume":"25","author":"CE Nelson","year":"2019","unstructured":"Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019;25:427\u201332.","journal-title":"Nat Med"},{"key":"394_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13543784.2021.1868434","volume":"30","author":"O Sheikh","year":"2021","unstructured":"Sheikh O, Yokota T, Developing. DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies. Expert Opin Investig Drugs. 2021;30:167\u201376.","journal-title":"Expert Opin Investig Drugs"},{"key":"394_CR39","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan D. Systemic AAV Micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther. 2018;26:2337\u201356.","journal-title":"Mol Ther"},{"key":"394_CR40","doi-asserted-by":"publisher","first-page":"R102","DOI":"10.1093\/hmg\/ddz128","volume":"28","author":"JM Crudele","year":"2019","unstructured":"Crudele JM, Chamberlain JS. AAV-based gene therapies for the muscular dystrophies. Hum Mol Genet. 2019;28:R102\u20137.","journal-title":"Hum Mol Genet"},{"key":"394_CR41","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"N Elangkovan","year":"2021","unstructured":"Elangkovan N, Dickson G. Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8:S303\u201316.","journal-title":"J Neuromuscul Dis"},{"key":"394_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nm1439","volume":"12","author":"P Gregorevic","year":"2006","unstructured":"Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haragushi M, Meuse L, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med. 2006;12:787\u20139.","journal-title":"Nat Med"},{"key":"394_CR43","doi-asserted-by":"publisher","first-page":"10657","DOI":"10.1021\/acs.jpcb.7b08938","volume":"121","author":"EM Houang","year":"2017","unstructured":"Houang EM, Bates FS, Sham YY, Metzger JM. All-Atom molecular Dynamics-Based analysis of Membrane-Stabilizing copolymer interactions with lipid bilayers probed under constant surface tensions. J Phys Chem B. 2017;121:10657\u201364.","journal-title":"J Phys Chem B"},{"key":"394_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13395-018-0177-7","volume":"8","author":"EM Houang","year":"2018","unstructured":"Houang EM, Sham YY, Bates FS, Metzger JM. Muscle membrane integrity in Duchenne muscular dystrophy: recent advances in copolymer-based muscle membrane stabilizers. Skelet Muscle. 2018;8:1\u201319.","journal-title":"Skelet Muscle"},{"key":"394_CR45","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1172\/JCI41329","volume":"120","author":"D Townsend","year":"2010","unstructured":"Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, et al. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest. 2010;120:1140\u201350.","journal-title":"J Clin Invest"},{"key":"394_CR46","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/nature03844","volume":"436","author":"S Yasuda","year":"2005","unstructured":"Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature. 2005;436:1025\u20139.","journal-title":"Nature"},{"key":"394_CR47","doi-asserted-by":"publisher","first-page":"15042","DOI":"10.1038\/mtm.2015.42","volume":"2","author":"EM Houang","year":"2015","unstructured":"Houang EM, Haman KJ, Filareto A, Perlingeiro RC, Bates FS, Lowe DA, et al. Membrane-stabilizing copolymers confer marked protection to dystrophic skeletal muscle in vivo. Mol Ther Methods Clin Dev. 2015;2:15042.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"394_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1586\/14779072.5.1.99","volume":"5","author":"D Townsend","year":"2007","unstructured":"Townsend D, Yasuda S, Metzger J. Cardiomyopathy of Duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach. Expert Rev Cardiovasc Ther. 2007;5:99\u2013109.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"394_CR49","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1089\/hum.2024.013","volume":"35","author":"S Baine","year":"2024","unstructured":"Baine S, Wier C, Lemmerman L, Cooper-Olson G, Kempton A, Haile A, et al. Long-term survival and myocardial function following systemic delivery of delandistrogene Moxeparvocec in Dmdmdx rats. Hum Gene Ther. 2024;35:978\u201388.","journal-title":"Hum Gene Ther"},{"key":"394_CR50","first-page":"617","volume":"65","author":"S Horn","year":"2024","unstructured":"Horn S, Fehse B. How safe is gene therapy: second death after Duchenne therapy. Inn Med. 2024;65:617\u201323.","journal-title":"Inn Med"},{"key":"394_CR51","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;31:3123\u20136.","journal-title":"Mol Ther"},{"key":"394_CR52","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31:332\u201341.","journal-title":"Nat Med"},{"key":"394_CR53","first-page":"759","volume":"10","author":"A Forand","year":"2025","unstructured":"Forand A, Moog S, Mougenot N, Lemaitre M, Sevoz-Couche C, Guesmia Z, et al. Long-term dystrophin replacement therapy in Duchenne muscular dystrophy causes cardiac inflammation. JACC Basic Trans Sci. 2025;10:759\u201382.","journal-title":"JACC Basic Trans Sci"},{"key":"394_CR54","first-page":"783","volume":"10","author":"D Townsend","year":"2025","unstructured":"Townsend D. Friend or foe: the immune system\u2019s dilemma with dystrophin replacement therapy. JACC Basic Trans Sci. 2025;10:783\u20135.","journal-title":"JACC Basic Trans Sci"}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-025-00394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13395-025-00394-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-025-00394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:36:56Z","timestamp":1757486216000},"score":1,"resource":{"primary":{"URL":"https:\/\/skeletalmusclejournal.biomedcentral.com\/articles\/10.1186\/s13395-025-00394-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1186\/s13395-025-00394-2","relation":{},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is review article, this is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}